3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
2
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Thymoma
1
Thymic epithelial tumor
1
Interventions
pembrolizumab
130
Carboplatin
106
Paclitaxel
65
Cisplatin
61
Gemcitabine
59
Pemetrexed
57
Bevacizumab
54
Docetaxel
49
Fluorouracil
43
Oxaliplatin
41
atezolizumab
37
Dexamethasone
36
Leucovorin
34
Cetuximab
33
130-nm albumin-bound paclitaxel
33
Nivolumab
30
Cyclophosphamide
30
Prednisone
29
Rituximab
28
Capecitabine
28
durvalumab
27
Fulvestrant
24
Lenalidomide
22
enzalutamide
21
Letrozole
21
Irinotecan
21
venetoclax
20
Doxorubicin
19
ribociclib
18
pomalidomide
18
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
AP 1903 reagent
×
30 days
×
Clear all
NCT07598955
2026-05-20
SELECT-NK-THYM
Beijing Biotech
Phase 1/2
Recruiting
36 enrolled